naltrexone/bupropion ER · Opioid antagonist/aminoketone antidepressant combination

Contrave

Label-safe COR-I efficacy remains primary, with broader brand range kept as attributed context.

Live fetch

Efficacy anchors

1 anchors

  • Label-safe anchor

    LabelWeek 56

    Trial: COR-I

    Adults with obesity or overweight with a weight-related comorbidity

    Brand-cited 56-week support range: 3.7% to 8.1%.

    5.4%

    Contrave DailyMed label

    Nov 10, 2025

    Why this number?

    DailyMed reports -5.4% mean body-weight change in COR-I; brand materials cite a broader 3.7% to 8.1% range across trials.

    Dose context: 32 mg/360 mg

Price anchors

1 anchors

  • CurAccess monthly cash price

    CurAccess

    Dose context: All doses

    Program: CurAccess Patient Support Program

    $99/mo

    Contrave savings page

    Apr 16, 2026 3:59 PM

    Why this number?

    $99 per month or less with free delivery through the CurAccess Patient Support Program.

    Official CurAccess patient-support price path.

    Patient segment: cash_pay

    Brand-operated CurAccess patient-support price path.

Source ledger

3 linked

Timeline

Change history

View all changes →
low severity

Observed Contrave price anchor curaccess_monthly

Observed Contrave curaccess_monthly at $99/month from Contrave savings page.

View source
low severity

Observed Contrave efficacy anchor label_absolute

Observed Contrave label_absolute efficacy anchor at 5.4% from Contrave DailyMed label.

View source